Endocrinology — MCQs

Endocrinology Indian Medical PG Practice Questions and MCQs

Question 141: When hypothyroidism is caused by pituitary dysfunction (Central hypothyroidism), what is the expected laboratory profile?

A. Goiter present, elevated TSH, low T3, T4
B. No goiter, reduced TSH, low T3, T4 (Correct Answer)
C. No goiter, elevated TSH, low T3, T4
D. Goiter present, reduced TSH, low T3, T4

Explanation: ### Explanation **1. Understanding the Correct Answer (Option B)** Central hypothyroidism occurs due to pathology in the pituitary gland (secondary) or hypothalamus (tertiary). In this condition, the pituitary fails to secrete adequate **Thyroid Stimulating Hormone (TSH)**. * **Hormonal Profile:** Low TSH leads to a lack of stimulation of the thyroid gland, resulting in **low T3 and T4** levels. (Note: TSH may occasionally be "inappropriately normal" but is functionally bio-inactive). * **Goiter Status:** TSH is a trophic hormone; it stimulates the growth of thyroid follicular cells. In central hypothyroidism, the lack of TSH leads to thyroid atrophy rather than hypertrophy. Therefore, **no goiter** is present. **2. Analysis of Incorrect Options** * **Option A & C:** Elevated TSH is the hallmark of **Primary Hypothyroidism** (e.g., Hashimoto’s thyroiditis). In primary failure, the pituitary attempts to compensate for low T4 by increasing TSH production via negative feedback. * **Option D:** A goiter requires a stimulatory factor (usually high TSH or TSH-receptor antibodies). It is physiologically inconsistent to have both low TSH and a goiter in a hypothyroid state. **3. NEET-PG High-Yield Pearls** * **The "Inappropriate" TSH:** In central hypothyroidism, TSH is usually low or low-normal. If you see low T4 with a "normal" TSH, suspect a pituitary cause. * **Rule Out ACTH Deficiency:** Before starting Levothyroxine in central hypothyroidism, always rule out or treat co-existing **adrenal insufficiency**. Giving T4 first can precipitate an acute adrenal crisis by increasing the metabolic clearance of cortisol. * **Monitoring:** Unlike primary hypothyroidism, you **cannot** use TSH to monitor treatment efficacy in central cases. You must monitor **Free T4** levels to adjust the dosage.

Question 142: Which of the following is NOT recommended as part of comprehensive medical care for patients with diabetes?

A. HbA1c testing, 2-4 times per year
B. Annual nutrition education
C. Blood insulin levels annually (Correct Answer)
D. Annual lipid profile

Explanation: **Explanation:** The management of Diabetes Mellitus focuses on glycemic control and the prevention of microvascular and macrovascular complications [2]. **Why Option C is correct:** Measuring **blood insulin levels** (fasting or stimulated) is **not recommended** for routine comprehensive care. In clinical practice, insulin levels are highly variable, expensive, and do not correlate directly with glycemic control or the risk of complications. Diagnosis and management are based on glucose levels (FPG, PPG) and HbA1c [1]. Insulin levels are primarily reserved for research or the differential diagnosis of hypoglycemia (e.g., Insulinoma). **Why the other options are incorrect:** * **HbA1c testing (Option A):** This is the gold standard for monitoring long-term glycemic control [2]. It is recommended at least **twice a year** in stable patients and **quarterly (4 times/year)** in those whose therapy has changed or who are not meeting targets. * **Annual nutrition education (Option B):** Medical Nutrition Therapy (MNT) is a cornerstone of diabetes care. Annual review with a dietitian helps reinforce lifestyle modifications and weight management [3]. * **Annual lipid profile (Option C):** Patients with diabetes are at high risk for atherosclerotic cardiovascular disease (ASCVD) [4]. An annual lipid profile is mandatory to decide on statin therapy and monitor cardiovascular risk. **High-Yield Clinical Pearls for NEET-PG:** * **Microalbuminuria screening:** Should be done annually (starting at diagnosis for Type 2, and 5 years after diagnosis for Type 1). * **Dilated Fundus Exam:** Annual screening for retinopathy is essential. * **BP Target:** Generally **<130/80 mmHg** according to recent ADA guidelines. * **Vaccination:** Patients with diabetes should receive annual **Influenza** vaccines and the **Pneumococcal** vaccine.

Question 143: Periodic paralysis is seen in the setting of hypokalemia (hypokalemic periodic paralysis). A similar type of paralysis is seen in the setting of which of the following conditions?

A. Hypothyroidism
B. Thyrotoxicosis (Correct Answer)
C. Hypoadrenalism
D. Cushing syndrome

Explanation: Explanation: Thyrotoxic Periodic Paralysis (TPP) is a rare but life-threatening complication of hyperthyroidism, most commonly seen in males of Asian descent. The underlying mechanism involves an intracellular shift of potassium rather than a total body deficit. 1. Why Thyrotoxicosis is Correct: Excess thyroid hormones ($T_3$ and $T_4$) increase the activity of the Na+/K+-ATPase pump. This leads to an influx of potassium from the extracellular fluid into the cells, resulting in acute hypokalemia [2]. This hyperpolarizes the muscle membrane, making it unexcitable and leading to flaccid paralysis [1]. Attacks are often triggered by high-carbohydrate meals (insulin also stimulates the Na+/K+ pump) or strenuous exercise [1]. 2. Why Other Options are Incorrect: * Hypothyroidism: Usually associated with muscle stiffness, cramps, and delayed relaxation of deep tendon reflexes (Woltman sign), but not acute periodic paralysis. * Hypoadrenalism (Addison’s Disease): Characterized by hyperkalemia due to aldosterone deficiency, which does not cause this specific clinical picture of hypokalemic periodic paralysis. * Cushing Syndrome: While chronic hypercortisolism can cause mild hypokalemia and proximal muscle wasting (myopathy), it does not typically present with acute, reversible episodes of periodic paralysis. High-Yield Clinical Pearls for NEET-PG: * Demographics: TPP has a strong male predilection (up to 20:1), despite hyperthyroidism being more common in females. * Treatment: The definitive treatment is achieving a euthyroid state (e.g., using Propranolol or antithyroid drugs) [2], [3]. * Caution: During an acute attack, potassium should be replaced cautiously to avoid "rebound hyperkalemia" once the shift reverses. * Diagnosis: Low urinary potassium excretion during an attack helps differentiate TPP from renal potassium loss.

Question 144: Which of the following is an indicator of osteoblastic activity?

A. Alkaline phosphatase (Correct Answer)
B. Osteocalcin
C. Hydroxyproline
D. Acid phosphatase

Explanation: Bone remodeling is a continuous process involving bone formation by **osteoblasts** and bone resorption by **osteoclasts** [4]. Markers of bone turnover are essential for diagnosing and monitoring metabolic bone diseases. **Correct Option: A. Alkaline Phosphatase (ALP)** Alkaline phosphatase is the most commonly used clinical marker for **osteoblastic activity**. Specifically, the **Bone-specific ALP (BALP)** isoenzyme is secreted by osteoblasts during the mineralization process [3]. It creates an alkaline environment necessary for the deposition of calcium hydroxyapatite [1]. While both ALP and Osteocalcin are markers of bone formation, ALP is the primary indicator used in standard clinical practice and exams for general osteoblastic activity. **Analysis of Incorrect Options:** * **B. Osteocalcin:** While this is a highly specific marker of bone formation (produced by mature osteoblasts), it is often considered a marker of **bone turnover** or late-stage maturation. In the context of standard medical exams, ALP remains the classic "indicator" of activity. * **C. Hydroxyproline:** This is a marker of **bone resorption (osteoclastic activity)**. It is a product of collagen breakdown released into the urine when bone matrix is degraded [2]. * **D. Acid Phosphatase:** Specifically **Tartrate-Resistant Acid Phosphatase (TRAP)**, this is a classic marker for **osteoclasts** [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Markers of Bone Formation (Osteoblastic):** Bone-specific ALP, Osteocalcin, and Procollagen type 1 N-terminal propeptide (P1NP). * **Markers of Bone Resorption (Osteoclastic):** Urinary Hydroxyproline, TRAP, and Serum C-telopeptide (CTX). * **Paget’s Disease:** Characterized by a massive isolated rise in ALP with normal Calcium and Phosphate levels. * **P1NP** is currently considered the most sensitive marker for monitoring osteoporosis treatment.

Question 145: A diabetic patient presents with liver cirrhosis and hyperpigmentation. What is the most likely diagnosis?

A. Wilson's disease
B. Hemochromatosis (Correct Answer)
C. Primary sclerosing cholangitis
D. Hepatitis B

Explanation: ### Explanation The clinical triad of **Diabetes Mellitus, Liver Cirrhosis, and Hyperpigmentation** is the classic presentation of **Hereditary Hemochromatosis**, often referred to as **"Bronze Diabetes."** [3] **1. Why Hemochromatosis is correct:** Hemochromatosis is an autosomal recessive disorder (most commonly involving the **HFE gene mutation**) characterized by excessive iron absorption. [3] The excess iron (hemosiderin) deposits in various organs, leading to: * **Pancreas:** Damage to islet cells causes secondary Diabetes Mellitus. [3] * **Liver:** Iron deposition leads to micronodular cirrhosis and increases the risk of Hepatocellular Carcinoma (HCC). [3] * **Skin:** Increased melanin production and iron deposition result in a characteristic metallic/bronze hyperpigmentation. [3] **2. Why other options are incorrect:** * **Wilson’s Disease:** Characterized by copper deposition. [2] While it causes cirrhosis, it typically presents with neuropsychiatric symptoms and **Kayser-Fleischer (KF) rings** in the cornea, not bronze skin or diabetes. [2] * **Primary Sclerosing Cholangitis (PSC):** An inflammatory condition of the bile ducts strongly associated with Ulcerative Colitis. It presents with jaundice and pruritus, not hyperpigmentation or diabetes. * **Hepatitis B:** A viral cause of cirrhosis. While it can cause systemic manifestations, it does not typically present with the specific triad of skin darkening and endocrine failure seen in iron overload. **3. NEET-PG High-Yield Pearls:** * **Screening Test:** Transferrin saturation (>45% is highly suggestive). * **Gold Standard Diagnosis:** Liver biopsy with **Prussian Blue staining** (quantifies iron) or identification of HFE mutations. [1] * **Most Common Cause of Death:** Heart failure (Restrictive Cardiomyopathy) or Hepatocellular Carcinoma. * **Treatment of Choice:** Therapeutic Phlebotomy (Iron chelation with Deferoxamine is used if phlebotomy is contraindicated). [1]

Question 146: A female presents with swelling in the neck, palpitations, and exophthalmos. Which of the following is the most likely diagnosis?

A. Granulomatous thyroiditis
B. Hashimoto thyroiditis
C. Graves disease (Correct Answer)
D. Multinodular goitre

Explanation: The clinical triad of **neck swelling (goiter)**, **palpitations (hyperthyroidism)**, and **exophthalmos (thyroid-associated ophthalmopathy)** is pathognomonic for **Graves’ Disease** [1], [3]. This is an autoimmune disorder caused by Thyroid Stimulating Immunoglobulins (TSI) that bind to and activate the TSH receptor, leading to excessive thyroid hormone production [1]. Exophthalmos is a specific extrathyroidal manifestation caused by the inflammation of retro-orbital tissues and fat, mediated by T-cells and fibroblasts [3], [4]. **Why other options are incorrect:** * **Granulomatous thyroiditis (De Quervain’s):** Typically presents with a **painful, tender thyroid** gland following a viral prodrome. While it can cause transient hyperthyroidism, it does not cause exophthalmos [2]. * **Hashimoto thyroiditis:** The most common cause of hypothyroidism. While it may present with a goiter, it typically features symptoms of low metabolism (weight gain, cold intolerance) rather than palpitations and exophthalmos. * **Multinodular goitre (MNG):** Presents as an enlarged, lumpy thyroid. While "Toxic MNG" can cause palpitations (hyperthyroidism), it lacks the autoimmune-mediated infiltrative features like exophthalmos. **High-Yield Clinical Pearls for NEET-PG:** * **Graves’ Triad:** Hyperthyroidism + Diffuse Goiter + Ophthalmopathy (Exophthalmos) [3]. * **Specific Sign:** **Pretibial Myxedema** (Dermopathy) is also highly specific to Graves’ [1]. * **Diagnosis:** Low TSH, High T3/T4, and **diffuse increased uptake** on Radioactive Iodine Uptake (RAIU) scan [2]. * **Antibody:** Anti-TSH receptor antibodies (TRAb/TSI) are the gold standard for confirmation [1].

Question 147: A 45-year-old man is diagnosed with diabetes for the first time. When should he visit an ophthalmologist?

A. On his 50th birthday
B. When dimness of vision starts
C. Before his 50th birthday
D. Immediately at the time of diagnosis (Correct Answer)

Explanation: The correct answer is **D. Immediately at the time of diagnosis.** **1. Why the correct answer is right:** In **Type 2 Diabetes Mellitus (T2DM)**, the exact onset of hyperglycemia is often asymptomatic and can occur years (typically 5–7 years) before a clinical diagnosis is made. Consequently, microvascular complications like diabetic retinopathy may already be present at the time of diagnosis [2]. Current clinical guidelines (ADA and AIOS) mandate a comprehensive dilated eye examination by an ophthalmologist **at the time of diagnosis** for all T2DM patients to screen for pre-existing damage [2]. **2. Why the incorrect options are wrong:** * **Options A & C:** Waiting until age 50 or any arbitrary age is dangerous, as retinopathy is duration-dependent, not age-dependent. Delaying screening increases the risk of irreversible vision loss [1]. * **Option B:** Diabetic retinopathy is often asymptomatic in its early, treatable stages (Non-Proliferative Diabetic Retinopathy) [2]. Waiting for "dimness of vision" usually means the disease has progressed to advanced stages like Macular Edema or Proliferative Diabetic Retinopathy, where the prognosis is significantly worse [1]. **3. High-Yield Clinical Pearls for NEET-PG:** * **Type 1 Diabetes:** Screening should begin **5 years after diagnosis** (as the onset of hyperglycemia is acute and known). * **Type 2 Diabetes:** Screening begins **at the time of diagnosis.** * **Pregnancy:** Women with pre-existing diabetes planning pregnancy should have an eye exam **pre-conception**, in the **first trimester**, and then be monitored every trimester. (Note: This does not apply to Gestational Diabetes). * **Follow-up:** If the initial exam is normal, repeat screening is generally recommended **annually**.

Question 148: Carcinoid syndrome is associated with all except?

A. Flushing of skin
B. Skin lesions like pellagra
C. VMA in urine (Correct Answer)
D. Bronchospasm

Explanation: **Explanation:** Carcinoid syndrome is caused by the systemic release of vasoactive substances (primarily **Serotonin**) from neuroendocrine tumors [1]. **Why "VMA in urine" is the correct answer:** Vanillylmandelic acid (VMA) is the end-metabolite of catecholamines (Epinephrine and Norepinephrine). Elevated urinary VMA is a diagnostic marker for **Pheochromocytoma**, not carcinoid syndrome. The gold-standard biochemical marker for Carcinoid syndrome is **5-HIAA (5-Hydroxyindoleacetic acid)**, which is the urinary metabolite of Serotonin. **Analysis of other options:** * **Flushing of skin:** This is the most common clinical feature (85% of cases), caused by the release of kinins and histamine [1]. * **Skin lesions like pellagra:** Carcinoid tumors divert up to 60% of the body's dietary **Tryptophan** to produce Serotonin. This leads to a deficiency in Niacin (Vitamin B3) synthesis, resulting in pellagra-like symptoms (Dermatitis, Diarrhea, Dementia) [2]. * **Bronchospasm:** Occurs in about 15% of patients due to the release of histamine and serotonin, manifesting as wheezing. **High-Yield Clinical Pearls for NEET-PG:** * **Primary Site:** Most common site for carcinoid tumors is the **Ileum** (small intestine). * **The Rule of Metastasis:** Carcinoid syndrome usually occurs only after the tumor has metastasized to the **liver**, as the liver otherwise metabolizes the bioactive substances via the portal circulation [1]. * **Cardiac Involvement:** Right-sided heart failure (Tricuspid regurgitation/Pulmonary stenosis) is common. Left-sided lesions are rare because the lungs metabolize serotonin. * **Treatment:** **Octreotide** (Somatostatin analogue) is the drug of choice to manage symptoms.

Question 149: What is the most common organ involved in Multiple Endocrine Neoplasia type 1 (MEN-1)?

A. Parathyroid (Correct Answer)
B. Thyroid
C. Adrenal
D. Testis

Explanation: **Explanation:** **Multiple Endocrine Neoplasia type 1 (MEN-1)**, also known as Wermer’s syndrome, is an autosomal dominant disorder caused by a mutation in the *MEN1* gene (encoding the protein Menin). It is classically characterized by the "3 Ps": **P**arathyroid, **P**ancreas, and **P**ituitary. 1. **Why Parathyroid is correct:** Primary Hyperparathyroidism (PHPT) is the **most common** and often the **earliest** clinical manifestation of MEN-1, occurring in over 95% of patients by age 40. Unlike sporadic cases, parathyroid involvement in MEN-1 typically presents as multiglandular hyperplasia rather than a single adenoma. 2. **Why other options are incorrect:** * **Thyroid:** While thyroid adenomas or goiters can occasionally be seen in MEN-1 patients, they are not a defining feature. Medullary thyroid carcinoma is a hallmark of **MEN-2**, not MEN-1. * **Adrenal:** Adrenal cortical tumors (usually non-functional) occur in about 20–40% of MEN-1 cases, making them less common than parathyroid involvement. * **Testis:** Testicular tumors are not a standard component of the MEN-1 clinical triad. **High-Yield Clinical Pearls for NEET-PG:** * **The 3 Ps of MEN-1:** Parathyroid (95%), Pancreatic Islet cells (e.g., Gastrinoma, Insulinoma - 40-70%), and Anterior Pituitary (e.g., Prolactinoma - 30-40%). * **Gastrinoma** (Zollinger-Ellison Syndrome) is the most common functional enteropancreatic neuroendocrine tumor in MEN-1. * **Screening:** If a patient presents with recurrent peptic ulcers and hypercalcemia, always suspect MEN-1. * **MEN-2A:** Medullary Thyroid CA + Pheochromocytoma + Parathyroid. * **MEN-2B:** Medullary Thyroid CA + Pheochromocytoma + Mucosal Neuromas/Marfanoid habitus.

Question 150: Which of the following is the most likely metabolic effect of insulin on adipose tissue?

A. Decrease in glucose transport
B. Decrease in glucose phosphorylation
C. Decrease in lipolysis (Correct Answer)
D. Decrease in lipoprotein lipase

Explanation: Insulin is the body’s primary anabolic hormone, functioning to store energy and prevent the breakdown of stored fuels. Its effect on adipose tissue is centered on promoting lipid storage and inhibiting lipid mobilization [2]. **Why "Decrease in lipolysis" is correct:** Insulin is a potent inhibitor of **Hormone-Sensitive Lipase (HSL)**. HSL is the enzyme responsible for breaking down stored triglycerides into free fatty acids and glycerol. By inhibiting HSL, insulin effectively **decreases lipolysis** [1], [4]. Simultaneously, insulin promotes the storage of fat by stimulating **Lipoprotein Lipase (LPL)**, which clears chylomicrons and VLDL from the blood to provide fatty acids for esterification within the adipocyte. **Analysis of Incorrect Options:** * **A & B: Decrease in glucose transport/phosphorylation:** These are incorrect because insulin **increases** glucose uptake in adipose tissue by recruiting **GLUT-4** transporters to the cell membrane [2], [4]. Once inside, insulin increases glucose phosphorylation (via hexokinase) to trap glucose for glycerol-3-phosphate production, which is essential for triglyceride synthesis [1], [4]. * **D: Decrease in lipoprotein lipase:** As mentioned, insulin **increases** LPL activity in adipose tissue to facilitate the uptake of exogenous fatty acids for storage. (Note: Insulin *decreases* LPL in muscle, diverting lipids toward storage rather than oxidation). **NEET-PG Clinical Pearls:** * **GLUT-4** is the only insulin-dependent glucose transporter (found in adipose tissue and skeletal muscle) [2]. * **Hormone-Sensitive Lipase (HSL)** is activated by glucagon, epinephrine, and ACTH (via cAMP), and inhibited by insulin [3], [4]. * **Lipodystrophy:** Repeated insulin injections at the same site can cause localized hypertrophy or atrophy of adipose tissue due to insulin’s potent lipogenic effects.

Practice by Chapter

Diabetes Mellitus

Practice Questions

Thyroid Disorders

Practice Questions

Adrenal Gland Disorders

Practice Questions

Pituitary Disorders

Practice Questions

Calcium and Bone Metabolism

Practice Questions

Reproductive Endocrinology

Practice Questions

Lipid Disorders

Practice Questions

Endocrine Hypertension

Practice Questions

Multiple Endocrine Neoplasia

Practice Questions

Obesity and Metabolic Syndrome

Practice Questions

Neuroendocrine Tumors

Practice Questions

Endocrine Emergencies

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free